重组人CXCR1/2拮抗剂G31P在人类疾病防治应用的研究进展  

Research progress on the application of G31P for prevention and control of human diseases

作　　者：闫文慧[1] 秦元华[1] 任一鑫[1] 崔昱[1] 

机构地区：[1]大连医科大学寄生虫病学教研室

出　　处：《国际医学寄生虫病杂志》2015年第5期295-301,共7页International JOurnal of Medical Parasitic Diseases

摘　　要：G31P（重组人CXCR1/2拮抗剂）是一种相对分子质量低的蛋白质，能与IL-8竞争结合其受体，导致IL-8与受体的生物学活性丧失，从而阻断中性粒细胞的趋化性及其引起的非特异性免疫应答，从而控制宿主炎症的发展。近年研究发现IL-8和其受体在肿瘤、心血管疾病和炎症反应性疾病，以及旋毛虫病和血吸虫病等疾病中高表达。探讨应用G31P控制炎症发展，以达到防治疾病的目的已成为目前国内外学者研究的热点之一。G31P （CXCR1/2 antagonist of human recombinant）, a kind of low molecular weight protein, can compete with IL-8 and combine with its receptors, leading to the loss of biological activities of IL-8 and its receptors, blocking the chemotaxis of neutrophils and nonspecific immune response, so as to control the devel-opment of the host inflammation. In recent years, studies found that IL-8 and its receptors were highly ex-pressed in diseases such as cancer, cardiovascular disease and inflammation disease, as well as trichinosis, schistosomiasis. The application of G31P to control inflammation development in order to achieve the purpose of prevention and treatment of disease has become one of hot topics in the study of scholars at home and abroad.

关 键 词：疾病 IL-8(3—72)K11R/G31P 白细胞介素-8 细胞表面趋化因子受体1/2 

分 类 号：R456[医药卫生—治疗学]